pdf   xlsx method abbreviations

renal cell cancer (RCC), atezolizumab plus bevacizumab , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

progression or deaths (PFS) 1.00 [0.69, 1.45]< 10%1 study (1/-)50.0 %NAnot evaluable important-
objective responses (ORR) 1.15 [0.63, 2.10]> 10%1 study (1/-)67.7 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 2.03 [0.07, 61.21]< 10%1 study (1/-)34.4 %NAnot evaluable non important-
AE (grade 3-4) 0.78 [0.43, 1.40]< 10%1 study (1/-)80.0 %NAnot evaluable non important-
AE leading to death (grade 5) 1.50 [0.25, 9.17]< 10%1 study (1/-)33.1 %NAnot evaluable non important-
TRAE (any grade) 0.38 [0.11, 1.25]< 10%1 study (1/-)94.4 %NAnot evaluable non important-
TRAE (grade 3-4) 0.49 [0.28, 0.87]< 10%1 study (1/-)99.3 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.49 [0.04, 5.49]< 10%1 study (1/-)71.7 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Colitis TRAE (grade 3-4) 0.99 [0.02, 50.39]< 10%1 study (1/-)50.2 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 0.99 [0.02, 50.39]< 10%1 study (1/-)50.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons